Cognivia, an AI company based in Belgium, has recently secured a significant investment to revolutionize pharmaceutical and biotech clinical research. The company aims to reshape the industry through the use of cutting-edge AI-ML algorithms that decode the relationship between patient traits and behaviors, ultimately expediting the development of innovative treatments. The investment, totaling €15.5 million, came from Vesalius Biocapital IV, SFPIM, and WE (Wallonie Entreprendre), and will allow Cognivia to deploy its predictive clinical trial solutions.
One of the critical areas that Cognivia’s solutions target is the placebo response, which has historically posed significant challenges to drug development. Cognivia’s Placebell™ utilizes predictive algorithms to mitigate the negative impact of the placebo response, thereby enhancing the study power of clinical trials. This innovation leads to increased success rates, reduced clinical trial timelines, and lower costs.
Additionally, Cognivia’s Compl-AI predicts the risk of non-compliance and dropout of patients during clinical trials, helping to strengthen and personalize patient engagement strategies. By understanding individual patient psychology and integrating these insights into the analysis of clinical trial data, Cognivia aims to optimize patient engagement and improve treatment outcomes.
The funding will catalyze Cognivia’s efforts to introduce its groundbreaking solutions to the market and establish a robust presence in the United States. The company plans to expand its team and establish a subsidiary in the US, fostering enhanced commercial and R&D collaborations. Cognivia also aims to strengthen its network through strategic alliances and by bolstering its advisory board with new members.
Vesalius Biocapital IV, SFPIM, and WE are esteemed investors who recognize the potential of Cognivia’s technologies. Olivier Houben, Partner at Vesalius Biocapital, expressed excitement about partnering with Cognivia and supporting their growth in the healthcare industry. This investment marks a pivotal moment for Cognivia and signifies a unique blend of industry experience and advanced AI capabilities.
Dominique Demolle, CEO and Co-founder of Cognivia, emphasized the company’s dedication to transforming the industry by making informed, data-driven decisions. Cognivia aims to empower clinicians, researchers, and industries to improve patient outcomes on a global scale.
Cognivia is the first and only company to combine quantification of patient psychology with AI and machine learning in order to improve the measurement of therapeutic efficacy. By harnessing “the power of the mind” and quantifying this unique phenomenon, Cognivia aims to improve clinical trial success rates, de-risk drug development, and ultimately advance healthcare.
With this recent investment and the addition of new members to the company’s operational team and strategic advisory committee, Cognivia is well-positioned to accelerate its efforts and deliver groundbreaking approaches in the field. The company’s commitment to becoming a leading partner for pharmaceutical and biotechnology companies highlights its dedication to address unmet patient needs.
Cognivia’s groundbreaking AI solutions have the potential to transform the pharmaceutical and biotech industry, creating new opportunities for innovation and improving patient outcomes. With this significant investment, Cognivia is poised to make a lasting impact in the field of drug development and healthcare.
Use the share button below if you liked it.